Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study [0.03%]
利布里珠单抗治疗从杜匹鲁玛或トラロキヌマブ换药的特应性皮炎患者：一项48周真实世界回顾性研究
Teppei Hagino,Hidehisa Saeki,Eita Fujimoto et al.
Teppei Hagino et al.
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold? [0.03%]
炎症性肠病的先进联合治疗：未来何去何从？
Piotr Eder,Adam Fabisiak,Hubert Zatorski et al.
Piotr Eder et al.
In recent years, substantial progress has been achieved in the development of novel therapeutic options for inflammatory bowel disease (IBD). Despite these advances, a significant proportion of patients continue to experience either primary...
Hemp-Derived Extracellular Vesicles: A Novel Frontier in Nanomedicine and Therapeutics [0.03%]
hemp衍生外泌体：纳米医学和治疗的新前沿
Hassan Azari,Hamid Moloudian,Nasser Koopaei et al.
Hassan Azari et al.
While mammalian-derived extracellular vesicles (EVs) face significant challenges in clinical translation due to scalability, cost, and safety, plant-derived EVs (PDEVs) have emerged as a promising alternative. This review focuses on EVs der...
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer: A Nationwide Cohort Study in France [0.03%]
法国全国范围内dMMR子宫内膜癌晚期或复发性患者的Dostarlimab联合化疗的真实世界应用：一项队列研究
Allison Singier,Stéphane Vignot,David Desplas et al.
Allison Singier et al.
Background: Dostarlimab, a PD-1 inhibitor, was initially approved in Europe in 2021 for advanced or recurrent mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) endometrial cancer. The phase III RUBY t...
Advances in Engineered Virus-Like Particles for Genome Editing and Therapy [0.03%]
工程化病毒样颗粒在基因组编辑和治疗中的进展
Se Hyeok Son,Seeone Woo,Ayeon Choi et al.
Se Hyeok Son et al.
Engineered virus-like particles (eVLPs) have emerged as a promising class of delivery systems for genome editing agents. By combining the efficient cellular entry of viral vectors with the safety advantages of nonviral platforms, eVLPs enab...
Navigating the Transition: A Scoping Review of System-Level Factors in Biosimilar Integration for Immune-Mediated Inflammatory Diseases [0.03%]
导航转换：免疫介导炎症疾病生物类似药整合的系统因素循证评价研究综述
Shania Kumar,Nicola Dalbeth,Chiara Gasteiger
Shania Kumar
Background: Patients with immune-mediated inflammatory diseases are routinely transitioned from originator biologics to biosimilars to reduce healthcare costs. While barriers related to patient and practitioner beliefs an...
Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future Directions [0.03%]
妇科肿瘤抗体药物偶联物的进展、挑战及未来方向
Taliya Lantsman,Ursula A Matulonis
Taliya Lantsman
Antibody-drug conjugates (ADCs) have emerged as an efficacious and promising treatment for advanced gynecologic cancers. These agents are an innovative treatment strategy that combines a monoclonal antibody, a linker, and a cytotoxic payloa...
Web of Potentials: Neuroactive Components of Spider Venom and Their Emerging Pharmacologic Applications in Neurologic Diseases [0.03%]
潜力蜘蛛网：蜘蛛毒液中的神经活性成分及其在神经系统疾病中的新兴药理学应用
Joshua Lawrence C Bautista,Elian Angelo M Abellanosa,Jaden G Jardiolin et al.
Joshua Lawrence C Bautista et al.
Spider venom has emerged as a promising source of neuroactive compounds with potential applications in the treatment of complex neurological disorders. With over 53,000 described species and more yet to be studied, spiders possess one of th...
Phase I Studies of HLX26, A Novel Anti-LAG-3 Antibody, Monotherapy or Combination Therapy in Patients with Advanced Solid Tumors [0.03%]
HLX26新型抗LAG-3单克隆抗体单药或联合疗法在晚期实体瘤患者中的I期研究
Rujiao Liu,Hui Jing,Yang Chen et al.
Rujiao Liu et al.
Background: HLX26 is a novel, recombinant humanized anti-LAG-3 IgG4 monoclonal antibody that exhibits high affinity for LAG-3 and demonstrates that it can block LAG-3 and its ligand interaction and activate T cells in pre...
The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis [0.03%]
OX40信号通路抑制作为特应性皮炎新治疗策略的作用机制研究
David Oliveira Dos Santos,Amir Mohamed,Adam Mohamed et al.
David Oliveira Dos Santos et al.
Atopic dermatitis is a chronic inflammatory skin disease affecting approximately 15-20% of children and 2-10% of adults worldwide. Epidermal barrier dysfunction and immune dysregulation are central to its pathogenesis, creating a self-perpe...